ID   Hs578T-Dox
AC   CVCL_IR02
SY   Hs578T/Doxo
DR   cancercelllines; CVCL_IR02
DR   Wikidata; Q54896337
RX   PubMed=7902062;
RX   PubMed=10571255;
RX   PubMed=15239129;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012612; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val157Phe (c.469G>T); ClinVar=VCV000012353; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Breast; UBERON=UBERON_0000310.
DI   NCIt; C4194; Invasive breast carcinoma of no special type
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0332 ! Hs 578T
SX   Female
AG   74Y
CA   Cancer cell line
DT   Created: 03-03-17; Last updated: 05-10-23; Version: 13
//
RX   PubMed=7902062;
RA   de la Torre M., Hao X.-Y., Larsson R., Nygren P., Tsuruo T.,
RA   Mannervik B., Bergh J.;
RT   "Characterization of four doxorubicin adapted human breast cancer cell
RT   lines with respect to chemotherapeutic drug sensitivity, drug
RT   resistance associated membrane proteins and glutathione
RT   transferases.";
RL   Anticancer Res. 13:1425-1430(1993).
//
RX   PubMed=10571255; DOI=10.1016/S0006-2952(99)00262-2;
RA   Jonsson O., Behnam-Motlagh P., Persson M., Henriksson R.,
RA   Grankvist K.;
RT   "Increase in doxorubicin cytotoxicity by carvedilol inhibition of
RT   P-glycoprotein activity.";
RL   Biochem. Pharmacol. 58:1801-1806(1999).
//
RX   PubMed=15239129; DOI=10.1002/ijc.20300;
RA   Cai C.-X., Chen J.-W.;
RT   "Overexpression of caveolin-1 induces alteration of multidrug
RT   resistance in Hs578T breast adenocarcinoma cells.";
RL   Int. J. Cancer 111:522-529(2004).
//